Welcome to our dedicated page for Serina Therapeutics news (Ticker: ser), a resource for investors and traders seeking the latest updates and insights on Serina Therapeutics stock.
Serina Therapeutics Inc (SER) is a clinical-stage biotechnology innovator advancing neurological and pain therapies through its proprietary POZ Platform technology. This page serves as the definitive source for official company announcements, research milestones, and financial updates.
Investors and industry observers will find timely updates on clinical trial progress, regulatory developments, and strategic partnerships. Our curated collection includes press releases on drug candidate advancements, peer-reviewed research findings, and executive commentary – all essential for understanding SER's position in biopharmaceutical innovation.
Key focus areas include updates on the POZ Platform's application in drug delivery systems, trial phase transitions, and collaborative research initiatives. Content is organized to provide clear context about how each development aligns with the company's mission to improve neurological and pain management therapies.
Bookmark this page for direct access to primary source materials from Serina Therapeutics. Check regularly for new insights into the company's scientific advancements and operational milestones in the competitive biotech landscape.
Serina Therapeutics (NYSE American: SER) has secured access to up to $20 million in financing through a convertible note agreement to advance its SER-252 clinical program for advanced Parkinson's disease. The funding, led by Board Director Greg Bailey, includes five tranches tied to clinical milestones and features 100% warrant coverage that could provide an additional $20 million if exercised.
The convertible notes have a 5-year maturity, 10% annual interest rate, and are convertible at $5.18 per share. The company plans to submit its U.S. IND application in Q4 2025 and begin patient dosing in Australia as part of its global registrational program. The SER-252-1b study is designed as a randomized, double-blind, placebo-controlled Phase 1b trial evaluating safety, tolerability, and pharmacokinetics in Parkinson's patients.
Serina Therapeutics (NYSE American: SER), a clinical-stage biotech company focused on its POZ Platform™ drug optimization technology, has announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference. CEO Steve Ledger will deliver a presentation on September 8, 2025, at 9:30 a.m. ET in New York.
The presentation will be available via live webcast for registered attendees, with an on-demand replay accessible for 90 days after the event.
Serina Therapeutics (NYSE American: SER) received positive FDA feedback supporting the advancement of SER-252, their POZ-enabled apomorphine treatment for advanced Parkinson's disease, through a 505(b)(2) NDA pathway. The company plans to initiate a registrational clinical study program with a comprehensive development strategy.
Key upcoming milestones include U.S. IND submission in Q4 2025, patient dosing in Australia in Q4 2025, and U.S. enrollment beginning in Q1 2026. The registrational study, SER-252-1b, is designed as a randomized, double-blind, placebo-controlled Phase 1b trial, evaluating safety, tolerability, and pharmacokinetics in Parkinson's disease patients with motor fluctuations.
Serina Therapeutics (NYSE American: SER) reported its Q2 2025 financial results and business updates. The company recorded a net loss of $6.4 million ($0.66 per share) compared to net income of $5.2 million in Q2 2024. Revenue increased to $130,000 from $51,000 year-over-year.
Key developments include the advancement of SER-270, a once-weekly injectable therapy for tardive dyskinesia, the appointment of Dr. Stephen Brannan to the Board, and securing $5 million in funding for SER-252 development. The company raised $1.2 million through ATM offerings and ended Q2 with $6.0 million in cash, expected to fund operations into Q4 2025.
Operating expenses increased to $5.7 million, with R&D expenses doubling to $3.2 million year-over-year. The company's lead candidate SER-252 for advanced Parkinson's disease is scheduled to enter clinical trials in Q4 2025.
Serina Therapeutics (NYSE:SER) announced the advancement of SER-270 (POZ-VMAT2i), a novel once-weekly injectable VMAT2 inhibitor for treating tardive dyskinesia (TD). The drug leverages Serina's proprietary POZ Platform™ technology to provide a long-acting alternative to daily oral medications.
The U.S. TD market, which exceeded $3.7 billion in sales in 2024, is projected to reach $5.4 billion by 2030. Currently, fewer than 30% of U.S. TD patients are diagnosed, with less than half receiving treatment. The company also plans to explore the drug's potential for treating chorea associated with Huntington's disease.
POZ-VMAT2i specifically targets underserved patients who struggle with daily medication adherence, institutionalized patients, and those with dysphagia, offering a potentially transformative solution in the VMAT2 inhibitor market.
Serina Therapeutics (NYSE American: SER), a clinical-stage biotech company focused on its proprietary POZ Platform™ drug optimization technology, has announced its participation in the upcoming BTIG Virtual Biotechnology Conference. CEO Steve Ledger will engage in a fireside chat on Tuesday, July 29, 2025, at 2:00 p.m. ET during the two-day conference scheduled for July 29-30, 2025.
Serina Therapeutics (NYSE American: SER), a clinical-stage biotech company developing SER-252 for advanced Parkinson's disease, has granted stock options to a new non-executive employee. The inducement grant consists of options to purchase 12,500 shares of common stock, with an exercise price matching the closing price on June 18, 2025.
The Option Grant, approved by Serina's Compensation Committee under the 2024 Inducement Equity Plan, aims to align employee interests with stockholders and was made in compliance with NYSE American's Company Guide Section 711(a).
Serina Therapeutics (NYSE American: SER), a clinical-stage biotechnology company, has announced its 2025 Annual Stockholders Meeting will be held on November 7, 2025. The specific time and location will be detailed in the company's definitive proxy statement to be filed with the SEC.
Due to the meeting date change of more than 30 days from the 2024 annual meeting anniversary, stockholder proposals under Rule 14a-8 must be submitted by 5:00 p.m. (Central Time) on August 15, 2025. For stockholder proposals and director nominations under the company's bylaws, submissions must be received between July 10, 2025, and August 9, 2025 at the company's Huntsville, Alabama headquarters.
Serina Therapeutics (NYSE American: SER) announced its CEO Steve Ledger will present at a FORCE Family Office investor webinar on June 26, 2025, at 12:00 p.m. ET. The presentation, titled "New Drug Optimization Platform to Transform Parkinson's Care," will focus on the company's drug candidate SER-252, a polymer conjugate of apomorphine designed to provide continuous dopaminergic stimulation for Parkinson's disease treatment.
The webinar will highlight the company's POZ Platform™ technology and its potential to improve safety, duration, and tolerability of Parkinson's treatments. The event will include a Q&A session hosted by FORCE Family Office CEO Steve Saltzstein.
FAQ
What is the current stock price of Serina Therapeutics (ser)?
What is the market cap of Serina Therapeutics (ser)?
